Abstract 193P
Background
Liposomal irinotecan + 5-fluorouracil/leucovorin (5-FU/LV) is approved for adults with metastatic pancreatic ductal adenocarcinoma (mPDAC) following progression with gemcitabine-based therapy. First-line (1L) liposomal irinotecan + 5-FU/LV + oxaliplatin (NALIRIFOX) is being investigated in a phase I/II trial of patients with locally advanced/mPDAC (NCT02551991). Serum CA 19-9 levels are typically elevated in patients with mPDAC and post-treatment reductions in CA 19-9 levels have been associated with prolonged survival. We report the results of an exploratory survival analysis from the phase I/II trial of 1L NALIRIFOX in mPDAC for subgroups defined by post-treatment changes in CA 19-9 level.
Methods
Eligible patients were adults with ECOG performance status (PS) ≤ 1 and adequate organ function who received 1L NALIRIFOX (liposomal irinotecan 50 mg/m2 (free base), 5-FU 2400 mg/m2, LV 400 mg/m2, oxaliplatin 60 mg/m2) on days 1 and 15 of each 28-day cycle. Tumors (RECIST v1.1) and serum CA 19-9 were assessed at screening, every 8 weeks and at end of treatment. Progression-free (PFS) and overall survival (OS) were compared for subgroups defined by best change in CA 19-9 level over the first 16 weeks of treatment (≥ 20% and ≥ 50% decrease; data cut-off 26 Feb 2020).
Results
In total, 32 patients were eligible for the trial, of whom 30 had a baseline CA 19-9 measurement (median [range] 315.5 [2–127115] U/mL) and 22 had a repeat CA 19-9 measurement by Week 16 (analysis set). Overall, NALIRIFOX reduced CA 19-9 level: median (range) best change of –49.4 (–100, +376)%. Median OS and PFS were numerically higher in patients with a CA 19-9 decrease ≥ 20% by Week 16 (Table) Table: 193P
All N = 32 | Analysis set n = 22 | Analysis set, by best change in CA 19-9 by Week 16 | ||||
≥ 20% decrease | ≥ 50% decrease | |||||
Yes n = 14 | No n = 8 | Yes n = 11 | No n = 11 | |||
PFS | ||||||
Progressed/died,a n (%) | 17 (53.1) | 12 (54.5) | 6 (42.9) | 6 (75.0) | 4 (36.4) | 8 (72.7) |
Median (95% CI) months | 9.2 (7.69, 11.96) | 9.6 (7.59, 32.30) | 32.3 (7.95, 32.30) | 7.6 (1.48, 9.56) | 11.2 (7.95, NE) | 7.6 (1.48, 32.30) |
HR (95% CI) | – | 0.13 (0.04, 0.50) | 0.33 (0.09, 1.12) | |||
OS | ||||||
Died, n (%) | 20 (62.5) | 14 (63.6) | 7 (50.0) | 7 (87.5) | 6 (54.6) | 8 (72.7) |
Median (95% CI) months | 12.6 (8.74, 18.69) | 12.7 (8.74, 22.54) | 22.5 (12.39, NE) | 8.2 (2.50, 18.69) | 22.5 (11.60, 22.54) | 9.2 (4.83, NE) |
HR (95% CI) | – | 0.24 (0.08, 0.75) | 0.55 (0.19, 1.60) |
a Patients who progressed/died after new therapy or >16 weeks after last non-progressive disease assessment were censored.
.Conclusions
1L NALIRIFOX reduced CA 19-9 levels in patients with locally advanced/mPDAC. CA 19-9 is a potential biomarker of post-NALIRIFOX outcomes in these patients.
Clinical trial identification
NCT02551991.
Editorial acknowledgement
Alison Chisholm of Oxford PharmaGenesis, Oxford, UK, provided medical writing and editorial support, which was sponsored by Ipsen, in accordance with Good Publication Practice guidelines.
Legal entity responsible for the study
Ipsen.
Funding
Ipsen.
Disclosure
A. Dean: Non-remunerated activity/ies: Shire; Non-remunerated activity/ies: Specialised Therapeutics; Travel/Accommodation/Expenses: Amgen. T. Bekaii-Saab: Advisory/Consultancy: Amgen; Advisory/Consultancy: Bayer; Advisory/Consultancy: Boehringer Ingelheim; Advisory/Consultancy: Celgene; Advisory/Consultancy: Genetech/Roche; Advisory/Consultancy: Glenmark; Speaker Bureau/Expert testimony: Lilly; Advisory/Consultancy: Merrimack; Advisory/Consultancy: NCCN; Advisory/Consultancy: Pfizer; Advisory/Consultancy: Research to Practice; Advisory/Consultancy: Sirtex Medical; Advisory/Consultancy: Taiho Pharmaceutical. P.M. Boland: Research grant/Funding (institution): Boehringer Ingelheim; Research grant/Funding (institution): Merck; Research grant/Funding (institution): Boston Biomedical; Research grant/Funding (institution): Genentech; Research grant/Funding (institution): Cascadian Therapeutics; Research grant/Funding (institution): Advaxis; Advisory/Consultancy, Research grant/Funding (institution): Bayer; Honoraria (self): Sirtex; Advisory/Consultancy: Merrimack. F. Dayyani: Speaker Bureau/Expert testimony, Research grant/Funding (institution): Amgen; Research grant/Funding (institution): AstraZeneca; Research grant/Funding (institution): Bristol-Meyers Sqibb; Advisory/Consultancy, Speaker Bureau/Expert testimony, Research grant/Funding (institution): Exelixis; Advisory/Consultancy, Speaker Bureau/Expert testimony, Research grant/Funding (institution): Ipsen; Research grant/Funding (institution): Taiho Pharmaceuticals; Advisory/Consultancy, Speaker Bureau/Expert testimony: Eisai; Advisory/Consultancy: Foundation Medecine; Advisory/Consultancy: Genentech; Advisory/Consultancy, Speaker Bureau/Expert testimony: Natera; Advisory/Consultancy: QED Therapetuics; Speaker Bureau/Expert testimony: Deciphera Pharmaceuticals; Speaker Bureau/Expert testimony: Sirtex Medical; Spouse/Financial dependant: Roche Diagnostics. T. Macarulla Mercade: Honoraria (self), Advisory/Consultancy: Genzyme; Honoraria (self), Speaker Bureau/Expert testimony: Sanofi; Honoraria (self), Research grant/Funding (institution): Roche; Honoraria (self): Tesaro; Honoraria (self), Advisory/Consultancy, Speaker Bureau/Expert testimony: Shire; Honoraria (self): Lilly; Honoraria (self): Ipsen; Advisory/Consultancy, Speaker Bureau/Expert testimony, Research grant/Funding (institution): Celgene; Advisory/Consultancy: QDE; Advisory/Consultancy: H3B; Advisory/Consultancy: Baxalta; Advisory/Consultancy: Incyte; Advisory/Consultancy: Servier; Research grant/Funding (institution): AstraZeneca; Research grant/Funding (institution): Agios; Research grant/Funding (institution): Aslan; Research grant/Funding (institution): Bayer; Research grant/Funding (institution): Genentech; Research grant/Funding (institution): Halozyme; Research grant/Funding (institution): Immunomedics. K. Mody: Research grant/Funding (institution): Agios; Research grant/Funding (institution): Senwha Biosciences; Research grant/Funding (institution): Taiho; Research grant/Funding (institution): ArQule; Advisory/Consultancy, Research grant/Funding (institution): AstraZeneca; Research grant/Funding (institution): Genentech; Research grant/Funding (institution): Incyte; Research grant/Funding (institution): MedImmune; Research grant/Funding (institution): Puma Biotechnology; Research grant/Funding (institution), award # NCI/NIH P50 CA210964: National Cancer Institute (NCI) of the National Institutes of Health; Advisory/Consultancy: Bayer; Advisory/Consultancy: Celgene; Advisory/Consultancy: Eisai; Advisory/Consultancy: Exelixis; Advisory/Consultancy: Ipsen; Advisory/Consultancy: Merrimack; Advisory/Consultancy: Vicus. B. Belanger: Full/Part-time employment: Ipsen. F. Maxwell: Shareholder/Stockholder/Stock options, Full/Part-time employment: Ipsen. Y. Moore: Leadership role, Shareholder/Stockholder/Stock options, Full/Part-time employment: Ipsen. T. Wang: Shareholder/Stockholder/Stock options, Full/Part-time employment: Ipsen. B. Zhang: Shareholder/Stockholder/Stock options, Licensing/Royalties, Full/Part-time employment: Ipsen. Z.A. Wainberg: Advisory/Consultancy: Ipsen; Advisory/Consultancy: Merck; Advisory/Consultancy: Lilly; Advisory/Consultancy: QED; Advisory/Consultancy: Daiichi; Advisory/Consultancy: AstraZeneca; Advisory/Consultancy: Bayer.
Resources from the same session
244P - Optimization of early diagnostics of cervical intraepitelial neoplasies and cervical cancer
Presenter: Zakhirova Nargiza
Session: e-Poster Display Session
245P - Clinicopathological features including response to platinum-based chemotherapy in endometrial carcinomas involving SWI/SNF complex inactivation.
Presenter: Izumi Tanimoto
Session: e-Poster Display Session
246P - Impact of genetically predicted elevated concentrations of C-reactive protein on ovarian cancer risk: A Mendelian randomization study
Presenter: Haoxin Peng
Session: e-Poster Display Session
247P - The role of p53 gene suppressor and bcl-2 oncoprotein in non-epithelial ovarian tumor prognosis determination among child and adolescent patients
Presenter: Anvar Shukullaev
Session: e-Poster Display Session
248P - The effect of progesterone on ALA-based PDT efficacy in uterine sarcoma cells
Presenter: Ellie Chu
Session: e-Poster Display Session
249P - A Retrospective Study on the Treatment Response of Locally Advanced Cervical Cancer Patients to Combination Chemoradiotherapy
Presenter: Siti Nabihah Sahralidin
Session: e-Poster Display Session
250P - Health-related Quality of Life in Women with Cervical Cancer
Presenter: Almagul Zhabagina
Session: e-Poster Display Session
251P - Tendency of morbidity and mortality in cervical cancer in the last 10 years in the Republic of Uzbekistan
Presenter: Mirzagaleb Tillyashaykhov
Session: e-Poster Display Session
252P - Secondary data analysis of newly diagnosed advanced ovarian cancer in South Korea
Presenter: Soo Young Jeong
Session: e-Poster Display Session
253P - Non-Epithelial Tumours of Ovary, An Experience from Qatar
Presenter: Ammar Madani
Session: e-Poster Display Session